Regional expansion Julphar is expanding beyond UAE into Saudi Arabia with a greenfield biologics and sterile facility and a long-term lease in Jeddah, signaling opportunities for regional distribution partnerships, contract manufacturing, and supply chain services in a high-growth market.

Strong revenue trajectory First-quarter 2026 net revenue of AED 273.4 million with improving profitability (EBITDA AED 44.5 million; net profit AED 28.4 million) indicates a stable customer base and potential for upsell of high-margin products, specialty generics, and injectable portfolios.

Manufacturing capacity Ten internationally accredited facilities producing over one million medicine boxes daily across tablets, syrups, suspensions, creams, injectables, and vaccines present numerous cross-sell opportunities, private-label ventures, and regional contract manufacturing deals.

Digital readiness Adoption of SAP Integrated Business Planning, SAP Extended Warehouse Management, SAP-backed operations, along with cloud and enterprise tech suggests readiness for data-driven sales approaches, demand forecasting partnerships, and integrated logistics proposals.

MOH approvals & partnerships Active MOH license LR-9 approvals and recent partnerships (e.g., with Modon) create openings for accredited suppliers, joint ventures, and compliance-aligned distribution channels in the Gulf region and neighboring markets.